Cargando…

ESBL production and carbapenem resistance increased the secondary bloodstream infection rates in intensive care units in Turkey, 2014–2019

AIM: Secondary bloodstream infections (SBSIs) are caused by another infection and differ from primary bloodstream infections (PBSIs) in terms of prevention and treatment strategies. The aim of this study was to determine the risk factors for bloodstream infections which were secondary to the most co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hekimoglu, Can Huseyin, Yildiz, Serap Suzuk, Sahan, Selda, Batir, Esen, Yildirim Gozel, Emine, Altun, Dilek, Pehlivanturk, Gulen, Comce, Muhammet, Kara, Fatih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	German Medical Science GMS Publishing House 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174877/ https://www.ncbi.nlm.nih.gov/pubmed/35707227 http://dx.doi.org/10.3205/dgkh000408

Ejemplares similares

COVID-19 outbreak control, example of ministry of health of Turkey
por: DEMİRBİLEK, Yasemin, et al.
Publicado: (2020)

479 Clinical outcomes in patients with extended-spectrum-beta-lactamase-producing (ESBL) Enterobacteriaceae bloodstream infections (ESB) treated with carbapenems (CP) and non-carbapenems (NC)
por: Chin, Judy, et al.
Publicado: (2014)

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

Carbapenem-Sparing Strategies for ESBL Producers: When and How
por: Karaiskos, Ilias, et al.
Publicado: (2020)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
por: Fukuchi, Takahiko, et al.
Publicado: (2016)

Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas
por: Parker, Jennifer K, et al.
Publicado: (2023)

Vaccine rejection and hesitation in Turkey
por: Özceylan, Gökmen, et al.
Publicado: (2020)

2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems
por: John, Reeba, et al.
Publicado: (2018)

Community-acquired antimicrobial resistance among Syrian refugees and the local population in Türkiye
por: Yıldız, Serap Süzük, et al.
Publicado: (2023)

ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019
por: Bandy, Altaf, et al.
Publicado: (2021)

The Characteristics of Extended-Spectrum β-Lactamases (ESBLs)-Producing Escherichia coli in Bloodstream Infection
por: Li, Rongrong, et al.
Publicado: (2023)

Intravascular papillary endothelial hyperplasia: histomorphological and immunohistochemical features
por: Akdur, Noyan Can, et al.
Publicado: (2013)

A ten-year review of ESBL and non-ESBL Escherichia coli bloodstream infections among children at a tertiary referral hospital in South Africa
por: Malande, Oliver Ombeva, et al.
Publicado: (2019)

Socioeconomic Burden of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacteriaceae
por: Zhu, Yunying, et al.
Publicado: (2021)

An outbreak investigation of Burkholderia cepacia infections related with contaminated chlorhexidine mouthwash solution in a tertiary care center in Turkey
por: Bilgin, Hüseyin, et al.
Publicado: (2021)

Prevalence of ESBL-Producing Enterobacteriaceae in Pediatric Bloodstream Infections: A Systematic Review and Meta-Analysis
por: Flokas, Myrto Eleni, et al.
Publicado: (2017)

Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence
por: Marra, Alexandre R, et al.
Publicado: (2006)

1153. ESBL Producing E. coli Urinary Tract Infections in Children: Is Carbapenem Always Necessary?
por: del Carmen, Ruiz Cabrales Diva, et al.
Publicado: (2021)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

1508. Carbapenem vs. Non-carbapenem as Empiric Regimens for Bacteremia Caused by ESBL Producing Escherichia coli and Klebsiella pneumoniae in Children: Preliminary Study
por: Park, Saera, et al.
Publicado: (2019)

Outcomes and Risk Factors of Bloodstream Infections Caused by Carbapenem-Resistant and Non-Carbapenem-Resistant Klebsiella pneumoniae in China
por: Liang, Xiaoxue, et al.
Publicado: (2022)

Seasonal Influenza Vaccine Effectiveness in Preventing Laboratory Confirmed Influenza in 2014-2015 Season in Turkey: A Test-Negative Case Control Study
por: Hekimoğlu, Can Hüseyin, et al.
Publicado: (2018)

Clinical and Mortality Risk Factors in Bloodstream Infections with Carbapenem-Resistant Enterobacteriaceae
por: Li, Xiaopeng, et al.
Publicado: (2017)

Nosocomial bloodstream infection and the emerging carbapenem-resistant pathogen Ralstonia insidiosa
por: Fang, Qingqing, et al.
Publicado: (2019)

Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections and Outcomes
por: Yuan, Youhua, et al.
Publicado: (2020)

Risk Factors for Bloodstream Infections Due to ESBL-Producing Escherichia coli, Klebsiella spp., and Proteus mirabilis
por: Vance, Mary Kathryn, et al.
Publicado: (2023)

2770. Investigating the Impact of Non-CTX-M Producing ESBL-E Bloodstream Infections on Patient Outcomes
por: Hareza, Dariusz A, et al.
Publicado: (2023)

Prevalence of ESBL-Producing Enterobacter Species Resistant to Carbapenems in Iran: A Systematic Review and Meta-Analysis
por: Khademi, Farzad, et al.
Publicado: (2022)

1199. Effectiveness of Non-carbapenem vs Carbapenems Empiric Therapy for Extended-Spectrum β-Lactamase (ESBL)-producing Enterobacterales (PE) Infections in Non-ICU patients: A Real-world Investigation in a Hospital with High-prevalence of ESBL-PE
por: Kang, Amy Y, et al.
Publicado: (2023)

Risk factors and influence of carbapenem exposure on the development of carbapenem resistant Pseudomonas aeruginosa bloodstream infections and infections at sterile sites
por: Barron, Michelle A., et al.
Publicado: (2016)

Clinical features of ESBL-producing E. coli responsible for bloodstream infections in French patients and molecular characterization of isolates
por: Gaultier, A, et al.
Publicado: (2015)

Characterization of Carbapenemase- and ESBL-Producing Gram-Negative Bacilli Isolated from Patients with Urinary Tract and Bloodstream Infections
por: Tickler, Isabella A., et al.
Publicado: (2023)

Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections
por: Lim, Tze-Peng, et al.
Publicado: (2018)

Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales
por: Ávila-Núñez, M., et al.
Publicado: (2023)

Risk Factors and Outcomes of Patients with Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infection
por: Wei, Xianzhen, et al.
Publicado: (2023)

1029. Increased Mortality in Hospital-Onset Carbapenem-Resistant Enterobacterales Bloodstream Infections
por: Boutzoukas, Angelique E, et al.
Publicado: (2023)

Carbapenem-Resistant Enterobacter hormaechei ST1103 with IMP-26 Carbapenemase and ESBL Gene bla(SHV-178)
por: Gou, Jian-Jun, et al.
Publicado: (2020)

838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
por: Stone, Tyler J, et al.
Publicado: (2020)

Molecular analyses of ADAMTS-1, -4, -5, and IL-17 a cytokine relationship in patients with ulcerative colitis
por: Buran, Tahir, et al.
Publicado: (2023)

Evaluation of carbapenem resistance using phenotypic and genotypic techniques in Enterobacteriaceae isolates
por: Sahin, Kazım, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e78dtapk5s17594345agfcvmc5